Nkarta tightens NKX019 dosing plan after first autoimmune readout, eyes FDA talks

Nkarta is proposing to shorten the dosing regimen for NKX019, its donor-derived CD19-targeted CAR NK cell therapy, after its first clinical look at systemic sclerosis and idiopathic inflammatory myopathy. The company presented the early Phase 1/2 findings at ACR Convergence on 9 November 2026, using data to 18 September.

Nkarta reported that levels of NKX019 in patients rose as the dose rose. It also said host T cells had started to recover before a dose planned for Day 7. On that basis it favours giving three doses on Days 0, 2 and 4, bringing the treatment forward into the first four days.

The material available does not include patient numbers, response rates or safety results, so the strength of the data cannot be assessed here. Those details should be checked against the full presentation before anyone draws conclusions about the programme's value.

Nkarta also intends to discuss a route to approval-enabling studies, and its choice of dose, with the US Food and Drug Administration. No timing or outline of the proposed development plan was given. As general context, a tighter schedule for an off-the-shelf product could simplify scheduling and supply planning, though Nkarta has not made that argument in the information reviewed.